ClinicalTrials.gg
CompletedNCT00360126Updated Mar 30, 2017Results posted

An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder

A Phase 4 interventional study of lamotrigine in Bipolar Disorder, sponsored by GlaxoSmithKline. Completed at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-30.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing lamotrigine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Lamotrigine · Bipolar Disorder.

Enrollment
32nd of 33
11 · median 72
Started
2005
with 3 others
Phase 4
13 of 33
none open now
Registered
15th of 33
by date
Lead sponsor
9 of 33
GlaxoSmithKline

Among the 33 studies testing lamotrigine in Bipolar Disorder, this one is the 32nd largest by enrollment, is one of 4 that started in 2005, is one of 13 in phase 4, and was the 15th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 33 studies testing lamotrigine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing lamotrigine in Bipolar Disorder as a file.
02

Study summary

The precursor study (SCA101469) was an open-label, prospective multicentre study in adult subjects diagnosed with bipolar disorder consisting of 36 weeks treatment with lamotrigine. The current study is to provide 12 months post study access to open-label lamotrigine for participants of the SCA101469 study.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Lamictal
  • lamotrigine
  • Open-Label Extension Study
  • Bipolar Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  • completed 32 weeks of open label treatment in study SCA101469 and, in the investigators opinion, has responded to lamotrigine therapy
  • male or female subject

A female is eligible to enter and participate in this study if she is of:

  1. non- (i.e., physiologically incapable of becoming pregnant, including any female who is or sterilised) or,
  2. child-bearing potential, has a negative urine pregnancy test at screening, and agrees to one of the following methods:

    • Complete abstinence from intercourse from 2 weeks prior to administration of the study drug, throughout the study, and for a time interval after completion of premature discontinuation from the study to account for elimination of the drug (a minimum of 5 half-lives or longer if the pharmacodynamic profile of the investigational drug warrants a longer time period); or,
    • Sterilisation of male partner; or,
    • Implants of levonorgestrel; or,
    • Injectable progestogen; or,
    • Oral contraceptive (combined or progestogen only); or,
    • Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year (not all IUDs meet this criterion); or,
    • Any other methods with published data showing that the lowest expected failure rate for that method is less than 1% per year; or,
    • Barrier method only if used in combination with any of the above acceptable methods.

      • willing and able to give written to participate in the study.

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  • subject experienced a 'mood episode' during participation in study SCA101469, or since completing participation in study SCA101469.
  • participation in a clinical drug trial other than SCA101469 within the past 30 days or previous participation in this clinical study
  • known to lamotrigine
  • in the investigator's judgement, the subject poses a current serious suicidal or homicidal risk, or has made a suicide attempt within the past 6 months.
  • combination of carbamazepine and valproate
  • concurrent lamotrigine therapy, other than that commenced in study SCA101469
  • current or history of substance abuse
  • diagnosis of epilepsy
  • diagnosis or history of an obsessive-compulsive disorder, social phobia, or eating disorder
  • significant cardiac, renal, cerebrovascular, or hepatic condition; no significant abnormalities in the laboratory tests or recording performed during study SCA101469.
  • unable to understand or implement instructions
  • unresolved drug related adverse event or serious adverse event occurring in study SCA101469
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs)

    An adverse event (AE) is defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event is therefore any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Only SAEs were recorded and reported in this extension study.

    Time frame: Up to 54 weeks

07

Results

Posted Mar 30, 2017

Participant flow

A total of 11 participants were enrolled and randomized from 13 October 2005 to 12 February 2007.

Participant flow — Overall Study
MilestoneLamotrigine
Started11
Completed11
Not completed0

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An adverse event (AE) is defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event is therefore any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Only SAEs were recorded and reported in this extension study.

Time frame:
Up to 54 weeks
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsLamotrigine
Number of Participants With Serious Adverse Events (SAEs)0

Adverse events

Collected over Up to 54 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lamotrigine—0/11 (0%)—

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lamotrigine
Mean45.64 ± 3.28
Sex: Female, Male
Sex: Female, Male(Participants)Lamotrigine
Female7
Male4
Region of Enrollment
Region of Enrollment(Participants)Lamotrigine
Australia11
08

Study locations

3 sites
  • GSK Investigational Site
    Greenwich, New South Wales 2065, Australia
  • GSK Investigational Site
    Everton Park, Queensland 4053, Australia
  • GSK Investigational Site
    New Farm, Queensland 4005, Australia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 10 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2006
First posted
Aug 3, 2006
Start
Oct 2005
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Results first posted
Mar 30, 2017
Last update
Mar 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00360126
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 3, 2006
Start date
Oct 2005
Primary completion
Feb 2007
Completion
Feb 2007
Results posted
Mar 30, 2017
Last update
Mar 30, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion